BEAM
Beam Therapeutics Inc.·Healthcare
28.64
3.506%(+0.97)
Market ClosedLast Updated: — ET
52W L: $15.3552W H: $36.44
BEAM NEWS
marketbeat.com
3d ago
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances
Beam Therapeutics NASDAQ: BEAM Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics license application for its sickle cell disease candidate possible as early as the end of this year.
globenewswire.com
5d ago
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and Reduction in Human Neutrophil Elastase Activity Post-BEAM-302 Treatment Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and Reduction in Human Neutrophil Elastase Activity Post-BEAM-302 Treatment
fool.com
5d ago
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?
Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.
gurufocus.com
May 13
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 PR Newswire DURHAM, N.C., May 13, 2026
prnewswire.com
May 13
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease. DURHAM, N.C.
seekingalpha.com
May 13
Beam Therapeutics: Base Editing Is Moving From Platform Story To Regulatory Asset Story
Beam Therapeutics is transitioning from a scientific platform to a late-stage genetic medicine company with a clear commercial bridge. BEAM's $1.2B cash position supports a runway into mid-2029, enabling pivotal programs in sickle cell disease (Risto-cel) and AATD (BEAM-302). Risto-cel targets process efficiency and efficacy in SCD, with a potential BLA submission by year-end 2026; BEAM-302 pursues accelerated approval in AATD.
